566169-97-9

Basic information

• Product Name: Benzenamine, 4-(6-bromo-2-benzothiazolyl)-
• CAS NO: 566169-97-9
• Molecular Formula: C13H9BrN2S
• Molecular Weight: 305.198
• Mol File: 566169-97-9.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: Benzenamine, 4-(6-bromo-2-benzothiazolyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 4-(6-bromo-2-benzothiazolyl)-(566169-97-9)
• EPA Substance Registry System: Benzenamine, 4-(6-bromo-2-benzothiazolyl)-(566169-97-9)

Safety Data

• Hazardous Substances Data: 566169-97-9(Hazardous Substances Data)

Usage

Description

Benzenamine, 4-(6-bromo-2-benzothiazolyl)-, also known as 4-(6-Bromo-2-benzothiazolyl)benzenamine, is a chemical compound with a unique molecular structure that features a benzenamine core and a 6-bromo-2-benzothiazolyl group attached to it. Benzenamine, 4-(6-bromo-2-benzothiazolyl)is known for its potential applications in various fields, particularly in the medical and pharmaceutical industries.

Uses

Used in Medical Imaging:
Benzenamine, 4-(6-bromo-2-benzothiazolyl)-, is used as a β-amyloid PET (positron emission tomography) tracer for the diagnosis of neurological diseases. Its application is particularly relevant in identifying and monitoring the progression of conditions such as Alzheimer's and Down's syndrome. Benzenamine, 4-(6-bromo-2-benzothiazolyl)-'s ability to act as a tracer allows for the visualization of β-amyloid plaques, which are a hallmark of these neurodegenerative diseases, thus aiding in early detection and treatment planning.

Upstream product

• 555-16-8 4-nitrobenzaldehdye 
• 23451-95-8 2-amino-5-bromobenzenethiol 
• 15864-32-1 2-amino-6-bromobenzothiazole 
• 182499-80-5 2,2′-disulfanediylbis(4-bromoaniline) 
• 122-04-3 4-nitro-benzoyl chloride 
• 106-40-1 4-bromo-aniline 
• 150-13-0 4-amino-benzoic acid 
• 1226795-30-7 2-(4'-nitrophenyl)-6-tributylstannylbenzothiazole 
• 43016-99-5 Tin (II) chloride 
• 566169-95-7 N-(4'-bromophenyl)-4-nitrothiobenzamide 
• 59280-03-4 N-(4'-bromophenyl)-4-nitrobenzamide 
• 566169-96-8 6-bromo-2-(4-nitrophenyl)benzo[d]thiazole 

Downstream Products

• 1226795-31-8 2-(4'-N-tert-butyloxycarbonyl-methylaminophenyl)-6-bromobenzothiazole 
• 566169-98-0 2-(4'-methylaminophenyl)-6-bromobenzothiazole 
• 1374349-51-5 N-[4-(6-bromobenzo[d]thiazol-2-yl)phenyl]-N-methylformamide 
• 1374349-35-5 4-(6-bromobenzo[d]thiazol-2-yl)-N-(⁽¹¹⁾C-methyl)aniline 
• 1374349-44-6 N-[4-(6-bromobenzo[d]thiazol-2-yl)phenyl]-N-(⁽¹¹⁾C-methyl)formamide 
• 1374349-53-7 N-[4-(6-bromobenzo[d]thiazol-2-yl)phenyl]formamide 

Relevant articles and documents

Development of a radioiodinated thioflavin-T-Congo-red hybrid probe for diagnosis of systemic amyloidosis

Introduction: Systemic amyloidosis is a group of diseases characterized by the deposition of amyloid protein in multiple organs throughout the body and causing their dysfunction. As amyloid deposition is observed at an early phase and is highly specific t

For the preparation and β Amyloid protein specific binding of the compound of compound, preparation method and application thereof (by machine translation)

One aspect of the invention discloses a compound, the compound has the structural formula X as shown in the structure, wherein the substituted group R1 Can be - NO2 It also can be thought that the - NHCH3 ; On the other ha

COMPOUND FOR SPECIFICALLY BINDING TO AMYLOID ?-PROTEIN

Provided is a compound for specifically binding to amyloid β-protein. The compound has thereon a nuclide with a large thermal neutron capture cross section and the compound is capable of specifically binding to the amyloid β-protein. The property of the compound allows it to be used in conjunction with a neutron capture therapy device to eliminate amyloid β-protein. Similarly, when the compound is labelled with radioactive element 11C, the compound can also be used in conjunction with PET/CT for determining the part of the brain where amyloid β-protein is deposited, for diagnosing Alzheimer's disease. Also disclosed is a preparation process for the compound. The beneficial effect of the present disclosure is to make the therapy and diagnosis of Alzheimer's disease more targeted by providing the compound for specifically binding to amyloid β-protein.